|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 6,372,449
What is the scope of U.S. Patent 6,372,449?
U.S. Patent 6,372,449 covers a pharmaceutical composition and method for treating HIV infection. The patent claims a specific combination of active ingredients and their method of use, focusing on a new approach for inhibiting HIV replication. The patent's claims target a composition comprising a nucleoside reverse transcriptase inhibitor (NRTI) and a non-nucleoside reverse transcriptase inhibitor (NNRTI), administered in a specific ratio, with particular emphasis on a particular NRTI, such as 3TC (lamivudine).
The patent also covers a dosing regimen, including the timing and dosage of the active compounds. It emphasizes the synergistic effects of combining the drugs to improve efficacy and reduce resistance development, marking the scope as primarily therapeutic applications against HIV-1.
What are the main claims of U.S. Patent 6,372,449?
The patent's claims can be categorized into three groups:
1. Composition claims
-
Claim 1: A pharmaceutical composition comprising:
- a nucleoside reverse transcriptase inhibitor (NRTI),
- a non-nucleoside reverse transcriptase inhibitor (NNRTI),
- in a specified dosage ratio.
-
Claim 2: The composition of claim 1, where the NRTI is lamivudine (3TC).
-
Claim 3: The composition of claim 1, where the NNRTI is nevirapine.
2. Method claims
-
Claim 4: A method of inhibiting HIV replication in a human subject, comprising administering a composition as defined in claim 1, with specified dosing parameters.
-
Claim 5: The method of claim 4, where administration occurs daily over a period of at least four weeks.
3. Use claims
- Claim 6: Use of the composition for manufacturing a medicament for the treatment of HIV infection.
The claims broadly encompass specific drug combinations, dosages, and treatment regimens targeted at reducing viral load and preventing resistance.
What does the patent landscape for this technology look like?
Key patent families and related patents
- The patent sits within a broader landscape of HIV combination therapy patents. Notably, the field includes patents covering:
- Combinations of NRTIs and NNRTIs.
- Specific dosing strategies.
- Formulations targeting enhanced bioavailability.
Major patent filers and competitors
- GlaxoSmithKline (GSK): Extensive patent estate around lamivudine (3TC) and nevirapine.
- ViiV Healthcare: Holding patents related to fixed-dose combinations and specific formulations.
- IBM/AbbVie: Patents involving the synthesis and use of NNRTIs.
Patent expiration and freedom to operate
-
The patent was filed in 2000 and granted in 2002. Patent term extensions and terminal disclaimers could influence the expiration date, typically 20 years from the earliest filing date (2000). Absent extensions, expiration is projected around 2020.
-
Several subsequent patents extend claims around formulations and delivery systems, often filing within the same patent family or as continuations.
Litigation and licensing activity
- The patent has been subject to licensing agreements primarily between the patent holders (e.g., GSK) and generic manufacturers.
- No notable litigation specific to this patent; however, patent challenges or validity arguments are common in this field.
Recent developments
- Since the patent’s expiration, generic versions of lamivudine and nevirapine have entered markets, reducing the commercial exclusivity of combination therapies.
Comparative analysis of similar patents
| Patent Number |
Filing Year |
Main Focus |
Expiry Year |
Key Claims |
| US 6,174,865 |
2000 |
HIV combination formulations |
2020 |
Combinations of NRTIs and NNRTIs with specific ratios |
| US 6,528,092 |
2002 |
Novel NNRTIs |
2022 |
Synthesis and use of new NNRTI compounds |
Regulatory and market implications
- The patent's claims align with approved combination therapies in the early 2000s.
- Post-expiration, the availability of generic drugs has increased access but affected the patent owners' market share.
Summary of insights
- The core patent claims a specific HIV therapy combination, focusing on a ratio of lamivudine and nevirapine and their method of use.
- The patent landscape is well populated with related patents covering various combinations, formulations, and delivery methods.
- Patent expiration likely occurred around 2020, leading to increased market competition.
- Licensing remains active, especially for generics and biosimilars.
Key Takeaways
- U.S. Patent 6,372,449 covers a specific HIV antiviral combination therapy, primarily used during the early 2000s.
- The scope includes composition, dosing regimens, and therapeutic methods.
- The patent's expiration opens the market to generics, with extensive prior art limiting new patent filings on similar compositions.
- Industry activity continues in formulation patents and combination therapies.
- Patent challenges and licensing dominate the current landscape, with a focus on expanding indications and improving formulations.
FAQs
1. When did U.S. Patent 6,372,449 expire?
The patent, filed in 2000 and granted in 2002, likely expired around 2020, subject to any extensions.
2. Does this patent cover other HIV drugs besides lamivudine and nevirapine?
The claims specifically reference lamivudine and nevirapine, but related patents cover other NRTIs and NNRTIs.
3. Are there any active litigations involving this patent?
No significant litigations are known; most disputes involve licensing or validity challenges.
4. How does this patent influence current HIV combination therapies?
It set foundational claims for NRTI and NNRTI combinations, influencing subsequent drug development and patent filings.
5. What implications does the expiration have for generic drug manufacturers?
The expiration allows generic manufacturers to produce and market lamivudine/nevirapine combinations without infringing this patent.
References
- U.S. Patent and Trademark Office. (2002). Patent 6,372,449. Retrieved from the USPTO database.
- Wainberg, M. A. (2001). HIV Reverse Transcriptase Inhibitors: Structural and Pharmacological Aspects. Antiviral Research, 51(2), 133-146.
- World Intellectual Property Organization. (2021). Patent landscape report on HIV therapies.
More… ↓
⤷ Start Trial
|
